VCYT Q3 2024 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$116M+28.6% YoY

Gross Profit

$79M68.2% margin

Operating Income

$12M10.4% margin

Net Income

$15M13.1% margin

EPS (Diluted)

$0.19

QoQ Revenue Growth

+1.3%

Cash Flow

Operating Cash Flow

$30M

Free Cash Flow

$28M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$99M

Stockholders' Equity

$1.2B

Cash & Equivalents

$274M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$116M	$90M	+28.6%
Gross Profit	$79M	$62M	+26.4%
Operating Income	$12M	-$32M	+137.9%
Net Income	$15M	-$30M	+151.2%

Revenue Segments

Testing

$110M95%

Product

$3M3%

Biopharmaceutical And Other

$3M3%